Plain-English translation of NCT06435910 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing personalized vaccines called DCvac that are made from your own immune cells and designed to fight multiple myeloma. After you've already received standard cancer treatment and your disease is in remission, you would receive multiple doses of these custom vaccines. The goal is to help your immune system stay alert and prevent the cancer from coming back.
Even when myeloma goes into remission with strong treatments like CAR-T therapy, the disease sometimes comes back. This trial exists because researchers want to find a way to help keep patients in remission longer by training the immune system to recognize and fight any remaining cancer cells before they cause relapse.
You likely qualify if…
You likely don't qualify if…
You would receive multiple injections of your personalized vaccine over time, with follow-up visits to monitor your health and check whether the treatment is working. The trial is small (enrolling about 10 patients) and focuses on checking whether the vaccine approach is safe and feasible. You'll need to be willing to stay in touch with the research team for ongoing monitoring and blood work.
AI-generated summary from trial data · Jun 26, 2026 · Not medical advice
China
Safety & dosing
Sponsor
Shenzhen Geno-Immune Medical Institute
Enrollment target
~10 participants
Started
May 2024
Primary completion
July 2027
Age range
18 Years – 80 Years
Last updated on clinicaltrials.gov in June 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Lung-Ji Chang, ph.D
Shenzhen Geno-Immune Medical Institute
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.